Q-omics provides the consensus-scored TRMT112P6 profile across patient tissues and cancer cell-line models. TRMT112P6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TRMT112P6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TRMT112P6 RNA expression shows 10,238 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight LIHC, KIRC, and READ as cancer lineages where TRMT112P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT112P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT112P6 survival associations across molecular data types. TRMT112P6 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT112P6 RNA expression–survival associations across cancer types. High TRMT112P6 expression shows unfavorable associations in LIHC, KICH, UVM and LGG, but favorable associations in KIRC and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TRMT112P6 RNA expression.
This table summarizes TRMT112P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRMT112P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT112P6 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, BRCA and THCA. The KIRC box plot shows higher TRMT112P6 RNA expression in tumor versus normal tissue (log2 FC = +0.535, t-test p < 0.001).
This table shows molecular features associated with TRMT112P6 in patient tissues and cancer cell lines. In patient samples, TRMT112P6 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
